Neurelis, Inc.

45 articles with Neurelis, Inc.

• STUDY PUBLISHED IN EPILEPSIA SHOWS SIGNIFICANT PROLONGATION OF TIME INTERVALS BETWEEN SEIZURE CLUSTERS TREATED WITH NEURELIS' VALTOCO® (DIAZEPAM NASAL SPRAY) CIV

  9/7/2022

  Neurelis, Inc., announced the recent online publication of a novel data analysis, evaluating the time interval between seizure clusters, or SEIzure interVAL (SEIVAL) in Epilepsia that indicates a significant increase in time between seizure clusters treated with VALTOCO® (diazepam nasal spray) CIV.

• NEURELIS STUDY PUBLISHED IN EPILEPSIA, A WORLD-CLASS JOURNAL DEDICATED TO EPILEPSY

  6/9/2022

  Neurelis, Inc., announced the publication of a study recently available online in the peer-reviewed, scientific journal Epilepsia.

• NEURELIS PRESENTED CLINICAL DATA SUPPORTING SEIZURE CLUSTER INTERVAL ANALYSIS AT THE EPILEPSY FOUNDATION PIPELINE CONFERENCE

  6/7/2022

  Neurelis, Inc., announced findings from a novel, investigational analysis of VALTOCO® (diazepam nasal spray) CIV.

• NEURELIS TO HIGHLIGHT VALTOCO (DIAZEPAM NASAL SPRAY) CIV DEVELOPMENT PROGRAM Updates AT 16TH EILAT CONFERENCE

  5/31/2022

  Neurelis, Inc., today announced it will provide highlights of its clinical development program for VALTOCO® (diazepam nasal spray), an acute therapy for episodes of frequent seizure activity (seizure clusters), at the 16th EILAT Conference on New Antiepileptic Drugs and Devices, Madrid Spain, May 22-25, 2022.

• DATA FROM NOVEL, EXPLORATORY ANALYSIS OF INTERMITTENT VALTOCO® (DIAZEPAM NASAL SPRAY) CIV USE INDICATES MORE THAN TWO-FOLD INCREASE IN MEAN INTERVAL BETWEEN SEIZURE CLUSTERS

  5/5/2022

  Neurelis, Inc., today announced findings from a novel, exploratory analysis of VALTOCO® (diazepam nasal spray).

• NEURELIS EXPANDS INTELLECTUAL PROPERTY ESTATE FOR VALTOCO®, A PATIENT-CENTRIC NASAL SPRAY FOR ACUTE TREATMENT OF EPISODES OF FREQUENT SEIZURE ACTIVITY

  4/26/2022

  Neurelis, Inc., announced that it has secured the issuance of United States Patent No. 11,241,414 (the '414 Patent) for VALTOCO® (diazepam nasal spray) CIV for acute treatment of episodes of frequent seizure activity in adult and pediatric patients age six and older. 

• Neurelis Announces Three Poster Presentations At The 2022 Annual Meeting Of The American Academy Of Neurology

  4/4/2022

  Neurelis, Inc., will present three posters from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity in patients with epilepsy ages 6 to 65 at the 73rd Annual Meeting of the American Academy of Neurology, April 2 to 7, in Seattle, Wash.

• 

  AbbVie, Sage and MT Pharma Anchor Weekend Highlights at AAN

  4/4/2022

  The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.

• NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN JAPAN AND THE ASIA-PACIFIC REGION

  1/25/2022

  Neurelis, Inc. announced that it has signed an exclusive licensing agreement with Aculys Pharma, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray) in Japan and the Asia-Pacific region which includes Australia, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, New Zealand, Philippines, South Korea, Thailand and Vietnam.

• Neurelis Announces 16 Poster Presentations at the Annual Meeting of the American Epilepsy Society

  12/2/2021

  Neurelis, Inc. will present a collection of 16 posters describing safety, tolerability and effectiveness results observed in trials evaluating VALTOCO® (diazepam nasal spray), and clinical trials designed to evaluate VALTOCO as a potential rescue therapy in patient groups with unmet needs at the annual meeting of the American Epilepsy Society December 3-7 in Chicago.

• Neurelis Announces Addition of Brittany Bradrick as CFO and Expansion of Leadership Team and Board of Directors

  10/18/2021

  Neurelis, Inc., announced today that it has made the following additions to its leadership team:

• Neurelis Announces Two Poster Presentations At The Annual Meeting Of The Child Neurology Society

  9/29/2021

  Neurelis, Inc. announced today that it is presenting two posters at the 50th Annual Meeting of the Child Neurology Society in Boston from September 29 through October 2.

• Neurelis Initiates Study Of VALTOCO® (diazepam nasal spray) In Children With Seizure Clusters Aged Two To Five

  9/20/2021

   Neurelis, Inc. announced today that it has initiated a clinical program to investigate the use of  VALTOCO® (diazepam nasal spray) in children with epilepsy aged two to five as a treatment for seizure clusters.

• Neurelis Announces Acquisition Of Rights To Portfolio Of New Chemical Entity (NCE) Compounds Targeting Cerebral Cavernous Malformations, A Rare CNS Disorder

  6/21/2021

  Neurelis, Inc., announced today that it has acquired from BioAxone Biosciences, Inc.

• Neurelis Announces Five Poster Presentations for the Annual Meeting of the American Academy Of Neurology

  4/19/2021

  Neurelis, Inc., announced today that it is presenting five posters at the American Academy of Neurology (AAN) Annual Meeting being held virtually from April 17 through April 22. 

• Neurelis Announces Two Poster Presentations for the Annual Meeting of the Academy of Managed Care Pharmacy

  4/12/2021

  Clinical studies support effectiveness and safety profile for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older

• 

  Money on the Move: March 10-16

  3/17/2021

  Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week.

• Neurelis Announces Close Of $114 Million Series D Financing Round To Advance Neuroscience Focus

  3/10/2021

  - 2021 financing will be a catalyst to further establish Neurelis as a best-in-class epilepsy company - Funds will enhance growth and commercial penetration of company's lead orphan drug product, VALTOCO® (diazepam nasal spray), and support pipeline development and expansion - Company also announces appointment of healthcare industry expert Alexander Kwit to its Board of Directors

• Neurelis Announces 12 Poster Presentations For The Annual Meeting Of The American Epilepsy Society

  12/4/2020

  Neurelis, Inc., announced today the company has 12 posters being presented at the American Epilepsy Society Annual Meeting being held virtually from December 4 through December 8.

• Neurelis Completes Pre-IND Meeting With FDA to Establish Clinical Development Program for NRL-4 in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar 1 Mania in Adults

  11/23/2020

  Neurelis, Inc., announced today that it has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) regarding NRL-4.